Novintum Bioscience Ltd logo

OCTIMET Oncology NV

OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.octimet.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Turnhoutseweg 30, 2340
Beerse
Belgium
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/octimet-oncology-nv” connections=”true” suffix=””]